Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

The weight-loss drug eloralintide shows up to 20% body weight reduction in trial, offering hope for obesity treatment beyond ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

FAT jabs could harm mum and baby if taken too close to pregnancy, a study suggests. Women who used the GLP-1 injections, such ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo Nordisk presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The ...

In the first quarter of 2018, there were less than five postpartum GLP-1 prescriptions, but by the second quarter of 2022, the number rose to 34 per 10,000 and sharply increased to 173 per 10,000 in ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. | Vanda Pharmaceuticals’ ...

Investors take the value of the company's shares back to where they stood in July 2021 following Novo Nordisk's announcement.